FDA grants priority review to enzalutamide for nonmetastatic HSPC
The application is specifically for use of enzalutamide in patients with nonmetastatic hormone-sensitive prostate cancer with high-risk biochemical recurrence and is supported by data from the phase 3 EMBARK trial.
Expert explains sequencing challenges in later-line renal cell carcinoma
Although the use of immunotherapy treatments continues to become more prevalent in advanced renal cell carcinoma, high-level evidence showing benefit of sequential administration of these agents is limited.
Trastuzumab deruxtecan shows antitumor activity in HER2+ tumors, including bladder cancer
The antibody-drug conjugate trastuzumab deruxtecan is being explored across a wide-range of HER2-positive solid tumors, including difficult-to-treat cancers.
Abemaciclib trial misses end point, but supports targeting CDK4/6 in mCRPC
The CDK4/6 inhibitor abemaciclib showed clinically activity in patients with heavily pretreated metastatic castration-resistant prostate cancer.
Enzalutamide plus leuprolide reduces risk of metastasis by nearly 60% in nonmetastatic HSPC
The 3- and 5-year MFS rates for those treated with enzalutamide plus leuprolide were 92.9% and 87.3%, respectively, compared with 83.5% and 71.4% for those given leuprolide alone.
Dr. Dallos discusses emerging treatments in the mCRPC paradigm
Antibody-drug conjugates, including those targeting PSMA, are among the next wave of treatment advances in mCRPC.
Social spending increase linked to better survival outcomes for black patients with cancer
Among patients with bladder cancer, increased public welfare spending led to an 8.18% survival increase for Black patients and a 44% closing of the disparity gap with white patients.
Novel PSMA-targeting fluorescent dye facilitates image-guided robotic prostatectomy
IS-002, an investigational, near-infrared, PSMA-targeting fluorophore, enhanced intraoperative cancer visualization during robotic prostatectomy.
Adjuvant nivolumab benefit in urothelial carcinoma sustained with longer follow-up
Adjuvant nivolumab continued to demonstrate a clinically meaningful disease-free survival benefit in patients with high-risk, muscle-invasive urothelial carcinoma, according to extended follow-up from the phase 3 CheckMate 274 trial.
Dr. Petrylak highlights the latest advances in metastatic urothelial cancer
In discussing treatment determinations, Petrylak noted that for patients with low PD-L1 expression had decreased survival benefits compared with patients treated with chemotherapy in the monotherapy arms of the phase 3 KEYNOTE-361 (NCT02853305) and phase 3 IMVIGOR-130 (NCT02807636) trials.
Erdafitinib combined with cetrelimab shows promise in bladder cancer
The TKI/immunotherapy combination demonstrated strong clinical activity in patients with metastatic or locally advanced urothelial carcinoma (mUC) harboring FGFR alterations.
Large surface area microparticle docetaxel shows promise in NMIBC
Phase 1/2 data showed that large surface area microparticle docetaxel is safe with early signs of clinical activity in patients with high-risk non–muscle invasive bladder cancer.
PSMA-targeted therapy shows early promise in locally advanced prostate cancer
Now that pivotal trials have demonstrated a survival benefit with PSMA-targeted therapy in metastatic prostate cancer, researchers are hoping to deliver the exciting new approach earlier in the disease course.
2 Clarke Drive Cranbury, NJ 08512